NCT00556699已完成1 期
An Open-Label, Phase Ib Study of the Safety, Pharmacokinetics, and Activity of the Anti-CD40 Monoclonal Antibody SGN-40 Administered in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma Who Have Relapsed Following Previous Rituximab Therapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 22
- 主要终点
- Incidence and nature of dose-limiting toxicities in order to determine the maximum tolerated dose
研究概览
简要总结
This is an open-label, multicenter Phase Ib study designed to evaluate the safety, pharmacokinetics, and preliminary efficacy of SGN-40 when combined with rituximab in patients with relapsed CD20-positive, follicular or marginal zone NHL who have received at least one prior rituximab-containing regimen.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Documented history of histologically confirmed CD20-positive, follicular NHL or marginal zone NHL
- •At least one previous treatment with rituxan monotherapy or a rituximab-containing regimen
- •Measurable disease
- •Either fresh or archived tumor specimen must be available for central confirmation of diagnosis and correlative studies
- •Life expectancy of > 3 months
- •For patients of reproductive potential, use of a reliable means of contraception
排除标准
- •Chemotherapy or radiotherapy within 28 days of Day 1
- •Prior treatment with a monoclonal antibody directed against CD40
- •Radioimmunotherapy or immunotherapy with a monoclonal antibody other than rituximab within 3 months of Day 1
- •Prior treatment with an investigational drug within 28 days of Day 1
- •Prior allogeneic bone marrow transplant
- •Prior autologous hematopoietic stem cell transplant within 12 weeks of Day 1
- •Concurrent systemic corticosteroid therapy
- •Prior anaphylactoid or other serious reaction to rituximab that resulted in hospitalization or discontinuation of therapy, or both
- •Evidence of clinically detectable ascites on Day 1
- •Other invasive malignancies within 3 years prior to Day 1 except for adequately treated basal cell or squamous cell skin cancer, in situ carcinoma of the cervix, in situ breast cancer, in situ prostate cancer, or other cancer of which the patient has been disease-free for at least 3 years
- •History or evidence on physical examination of CNS disease
- •Active infection requiring parenteral antibiotics within 14 days of Day 1
- •Major surgical procedure (excluding lymph node biopsy) or significant traumatic injury within 28 days prior to Day 1
- •Pregnancy (positive pregnancy test) or lactation
- •Serious, nonhealing wound, ulcer, or bone fracture
- •Clinically significant cardiovascular disease, congestive heart failure, serious cardiac arrhythmia requiring medication within 1 year prior to Day
- •Grade II or greater peripheral vascular disease at study entry.
- •Known human immunodeficiency virus (HIV) infection
- •Known serious medical conditions, including cirrhosis, hepatitis C infection, and chronic obstructive or chronic restrictive pulmonary disease
研究组 & 干预措施
1
Experimental
干预措施: rituximab (Drug)
1
Experimental
干预措施: SGN-40 (Drug)
结局指标
主要结局
Incidence and nature of dose-limiting toxicities in order to determine the maximum tolerated dose
时间窗: Length of study
次要结局
- Pharmacokinetic parameters(Length of study)
- Changes in vital signs, physical examination findings, and clinical laboratory results(Length of study)
- Incidence, nature, and severity of adverse events(Length of study)
- Duration of response(Length of study)
- Patient's best response as assessed by the investigator(Length of study)
- Event-free survival(Length of study)
研究者
相似试验
已完成
1 期
A Study of Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic FunctionCancerNCT01546519Genentech, Inc.31
招募中
1 期
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple MyelomaMultiple MyelomaNCT04910568Genentech, Inc.186
已完成
1 期
Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid TumorsSolid TumorsNCT01988896Hoffmann-La Roche153
已完成
1 期
A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic ArthritisJuvenile Idiopathic ArthritisNCT01904292Hoffmann-La Roche52
已完成
1 期
A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic MelanomaMetastatic MelanomaNCT03875079Hoffmann-La Roche83